December 24, 2018
GSK to list consumer healthcare on the UK equity market
GSK intends to separate the Joint Venture via a demerger of its equity interest and a listing of GSK Consumer Healthcare on the UK equity market.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
December 21, 2018
PLx Pharma’s largest shareholder, Park West, commits $15 million, to help get Vazalore closer to market
PLx Pharma’s largest shareholder, Park West Asset Management LLC, has purchased 15,000 shares of newly issued Series A Preferred Stock, for $15 million.
December 21, 2018
ObsEva in third phase testing looks at long term administration of linzagolix
ObsEva is evaluating long term administration of linzagolix in two dosing regimens with recruited patients for third phase of testing oral gonadotropin releasing hormone (GnRH) receptor antagonist Linzagolix.
December 21, 2018
Novartis in $2.1 billion Endocyte buy, adds to its oncology pipeline
In addition to yesterda’s announcement of moving to buy CAR-T cell producer CellforCure from LFB, Novartis today announced that it acquired another biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment, the US based Endocyte, Inc.
December 21, 2018
AstraZeneca-s Bevespi Aerosphere inhaler to treat COPD
AstraZeneca today announced that the European Commission (EC) has approved Bevespi Aerosphere in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
December 21, 2018
Veritas Pharma, Indigenous Bloom exchange a number of shares
Veritas Pharma has made a deal to exchange 41.6 million shares to three separate individuals at $0.12 per share, for their 2 million per $2.5 per share.
December 20, 2018
Novartis moves to buy CAR-T cell producer CellforCure from LFB
Novartis today revealed its offer to buy a French contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe, Cellforcure.
December 20, 2018
Novartis opens door to new Oncology CEO
Novartis announced today that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology, and will join the Executive Committee in the beginning of new year. Liz Barrett will be stepping down as CEO of Novartis Oncology.
December 20, 2018
GenomOncology names CEO
GenomOncology, a technology solution provider for oncology, named Brad Wertz as the new Chairman and Chief Executive Officer (CEO), who’ll assume the position from the start of year 2019. Wertz has been a founding investor and chairman of the board since the beginning, and has increased his involvement as the company has grown over the past two years.
December 19, 2018
AZ nets $70M after FDA’s new approval for Lynparza
AstraZeneca and Merck’s work on Lynparza is looking at mroe financial return after the US Food and Drug Administration (FDA) approved it for for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer.